Alternative rapamycin treatment regimens mitigate the impact of rapamycin on glucose homeostasis and the immune system

Inhibition of the mechanistic target of rapamycin (mTOR) signaling pathway by the FDA‐approved drug rapamycin has been shown to promote lifespan and delay age‐related diseases in model organisms including mice. Unfortunately, rapamycin has potentially serious side effects in humans, including glucos...

Descripción completa

Detalles Bibliográficos
Autores principales: Arriola Apelo, Sebastian I., Neuman, Joshua C., Baar, Emma L., Syed, Faizan A., Cummings, Nicole E., Brar, Harpreet K., Pumper, Cassidy P., Kimple, Michelle E., Lamming, Dudley W.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2015
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4717280/
https://www.ncbi.nlm.nih.gov/pubmed/26463117
http://dx.doi.org/10.1111/acel.12405

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4717280/
https://www.ncbi.nlm.nih.gov/pubmed/26463117
http://dx.doi.org/10.1111/acel.12405

Ejemplares similares